SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-018545
Filing Date
2023-05-22
Accepted
2023-05-22 16:16:05
Documents
55
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1082124
2 ex31-1.htm EX-31.1 18544
3 ex31-2.htm EX-31.2 18371
4 ex32-1.htm EX-32.1 7891
5 ex32-2.htm EX-32.2 5018
  Complete submission text file 0001493152-23-018545.txt   6438714

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE rspi-20230331.xsd EX-101.SCH 52084
7 XBRL CALCULATION FILE rspi-20230331_cal.xml EX-101.CAL 33286
8 XBRL DEFINITION FILE rspi-20230331_def.xml EX-101.DEF 261555
9 XBRL LABEL FILE rspi-20230331_lab.xml EX-101.LAB 396555
10 XBRL PRESENTATION FILE rspi-20230331_pre.xml EX-101.PRE 313463
49 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1128837
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-16467 | Film No.: 23944632
SIC: 2834 Pharmaceutical Preparations